<DOC>
	<DOCNO>NCT02094378</DOCNO>
	<brief_summary>The purpose study assess cognitive effect associate administration intranasal esketamine 84 mg .</brief_summary>
	<brief_title>A Study Evaluate Effect Intranasal Esketamine Cognitive Functioning Healthy Subjects</brief_title>
	<detailed_description>This randomize ( participant assign 1 2 treatment sequence chance ) , double-blind ( identity study drug know participant member study staff ) , placebo-controlled ( substance without active drug identical appearance esketamine ) , 2-period crossover study ( participant assign treatment sequence receive 1 dose esketamine 1 dose placebo administer intranasally [ nose ] ) conduct healthy adult participant single center . Participants complete 3 study phase : A screen phase 3 week ; 2-week double-blind treatment phase , include 2 treatment period ( Periods 1 2 ) separate washout interval least 7 day ; , 1-week posttreatment ( follow ) phase , applicable . The duration study participant approximately 6 week . Blood urine sample collect study laboratory assessment . Participants monitor safety time sign informed consent form 1 week last dose study drug ( end treatment ) .</detailed_description>
	<criteria>Body mass index ( BMI ) ( weight [ kg ] /height [ m2 ] ) 18 30 kg/m2 ( inclusive ) , body weight less 45 kg Blood pressure ( subject supine 5 minute ) 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic Screening predose Day 1 Period 1 A 12lead ECG consistent normal cardiac conduction function Screening predose Day 1 Period 1 Comfortable selfadministration intranasal medication able follow instruction provide Nonsmoker least 6 month first study drug administration Subject clinically significant liver renal insufficiency ; cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance . A significant primary sleep disorder exclusionary Clinically significant abnormal value hematology , clinical chemistry , urinalysis screen Day 1 Period 1 , deem appropriate investigator Clinically significant abnormal physical examination , vital sign , 12lead ECG screen Day 1 Period 1 , deem appropriate investigator Anatomical medical condition may impede delivery absorption study medication ( e.g. , undergone facial reconstruction , rhinoplasty , significant structural functional abnormality nose upper airway ; obstruction mucosal lesion nostril nasal passage ; undergone sinus surgery previous 2 year ; sign symptom rhinitis predose Day 1 Period 1 ) Has abnormal deviate nasal septum 1 follow symptom : blockage 1 nostril , nasal congestion ( especially 1sided ) , frequent nosebleed , frequent sinus infection , time facial pain , headache , postnasal drip</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Cognitive functioning</keyword>
</DOC>